Investopedia. Stockholders' equity, also referred to as shareholders' or owners' equity, is the remaining amount of assets available to shareholders after all liabilities have been paid. It is calculated either as a firm's total assets less its total liabilities or alternatively as the sum of share capital and retained earnings less treasury shares....
GTHX has been trading in a range for a while, and seems to have bottomed. The weekly MACD has done a bullish cross, and I think there is a good chance that it will breakout of its range toward the volume areas I have marked. I have plotted the price action that took place the last time it left this range. I think there is a reasonable chance that it hits ~$15, but...
trend reversal and the 3rd wave upcoming, uptrend might start from earnings, positive revenue in 2020-21 may cause a reprice
NASDAQ:GTHX 1. Inverted HnS be careful. Pharma companies can be unpredictable. It also can follow pharma index XBI
Good sign with the bounce off the support line. However, it was with LOW VOLUME. IMO, still not completely convinced. Still a good one to either take the chance and go LONG or add to the watchlist. Potential to DOUBLE position value to even TRIPLE position value over several months time.
Notice how many times price has been rejected from the pink line -- and also notice how price is now above that resistance! EASY 100% gains from this point onward!
NASDAQ:GTHX Possible Scenario: SHORT Evidence: Overbought RSI. Bearish Divergence * It's trading higher without any specific news, will drop soon. It's my opinion and could be wrong 100%
Not sure about this one. Volatile as hell and weak (ish) buy signals. Analysts going mad for it tho... Any thoughts..?
Earnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented...
paints quite a different picture. The ABC is not quite complete yet. There is a potential drop from $21 to $12.
GTHX: g1 therapeutics inc 2018-03-05 06:00:22 Detected possible positive results in drug trial